About Taj Oncology
Taj Oncology is a Healthcare company based in Mumbai (India) founded in 2009. Manufacturer of generic oncology products and biosimilars in India. Its Indian entity Taj Pharmaceuticals Limited reported revenue of ₹6.31 Cr. Taj Oncology offers products and services including Imatinib Mesylate and Hydroxyurea. Its focus areas include Biotechnology, Biosimilars, Cancer Therapies and Pharmaceuticals.
Company details
Taj Oncology is identified as a leading manufacturer of generic oncology products and biosimilars, with a broad portfolio focused on providing affordable, high-quality treatments for cancer. Efforts are made to reduce healthcare costs and improve patient quality of life through innovative pharmaceutical offerings. The company emphasizes research and development to discover new therapies and maintains collaborations for advanced cancer care, while ensuring compliance with regulatory standards.
- Headquarters Mumbai, India
- SectorsHealthcare
- Email••••••••
- Website tajoncology.com
- Legal Name Taj Pharmaceuticals Limited
- Date of Incorporation 05 Nov, 2004
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹6.31 Cr
FY 2024 · +31% YoY
- Net Profit₹10.7 Lakh
FY 2024 · 2% margin
- EBITDA₹1.30 Cr
FY 2024 · 21% margin
Associated legal entities of Taj Oncology
Taj Oncology operates through Taj Pharmaceuticals Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Taj Pharmaceuticals Limited CIN U24230MH2004PLC149424 | Active | 05 Nov 2004 | Mumbai, Maharashtra | ₹6.3 Cr | 3 | View details |
Products & Services of Taj Oncology
Taj Oncology offers a comprehensive portfolio of products and services, including Imatinib Mesylate and Hydroxyurea.
Imatinib Mesylate is utilized to treat certain types of leukemia and is produced as a protein-tyrosine kinase inhibitor that inhibits abnormal cell proliferation.
Hydroxyurea is employed to treat cancers like melanoma and leukemia and is manufactured by interfering with cell replication to reduce tumor growth.
Board of directors of Taj Pharmaceuticals Limited (Taj Oncology)
Taj Pharmaceuticals Limited is the primary company behind Taj Oncology. The board of Taj Pharmaceuticals Limited currently have 3 directors; the longest-serving is Ranvir Kumar Bindeshwari Singh, appointed in 2004. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ranvir Kumar Bindeshwari Singh DIN 01725251 | Director | 05 Nov 2004 | 22 yrs | Taj Pharmaceuticals Limited |
| Abhishek Ranvir Singh DIN 02706332 | Director | 10 Mar 2009 | 17 yrs 8 mo | Taj Pharmaceuticals Limited |
| Sudheer Singh DIN 06795666 | Director | 21 May 2013 | 13 yrs 5 mo | Taj Pharmaceuticals Limited |
Financials of Taj Oncology
Figures of Taj Pharmaceuticals Limited, the primary company behind Taj Oncology, for FY 2024. Revenue was ₹6.31 Cr (+31% year on year). Net profit was ₹10.7 Lakh (2% margin). EBITDA was ₹1.30 Cr (21% margin). Revenue has grown at a compounded annual rate of +23% over three years and +3% over five years.
- ₹6.31 CrRevenue · FY 2024 · +31% YoY
- ₹10.7 LakhNet profit · 2% margin
- ₹1.30 CrEBITDA · 21% margin
- ₹1.05 CrPaid-up capital
- +23%Revenue CAGR, 3 years
- +3%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Taj Pharmaceuticals Limited are on its company page.
Detailed financial statements for Taj Oncology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Taj Oncology
The website of Taj Oncology (tajoncology.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 10.9% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Taj Oncology
Complete news archive for Taj Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Taj Oncology
Taj Oncology was founded in 2009.
Taj Oncology is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind Taj Oncology, Taj Pharmaceuticals Limited, reported revenue of ₹6.31 Cr for FY 2024, up 31% year on year.
Taj Oncology is identified as a leading manufacturer of generic oncology products and biosimilars, with a broad portfolio focused on providing affordable, high-quality treatments for cancer. Efforts are made to reduce healthcare costs and improve patient quality of life through innovative pharmaceutical offerings. The company emphasizes research and development to discover new therapies and maintains collaborations for advanced cancer care, while ensuring compliance with regulatory standards.
Taj Oncology offers Imatinib Mesylate and Hydroxyurea.
Taj Oncology operates through Taj Pharmaceuticals Limited.
The legal entities of Taj Oncology currently have 3 directors, including Ranvir Kumar Bindeshwari Singh, Abhishek Ranvir Singh, Sudheer Singh.